-transparent.png){kind=logo}
OBJECTIVE We evaluated an In-house assay for HIV-1 drug resistance genotyping by using DBS samples in China. METHODS The amplification sensitivity was assessed using 79 DBS specimens with plasma viral load ranging from 1,000 to 6,000 copies/ml. Precision was assessed using 5 DBS specimens with 5 replicates tested in one test run. Reproducibility was evaluated using other 5 DBS specimens with 5 replicates genotyped in 5 test runs. Nucleotide sequence identity and the degree of concordance in detecting drug resistance mutations were assessed within and between test runs. In addition, nucleotide sequence and drug resistance mutations were compared between 64 matched plasma and DBS specimens. RESULTS The amplification rate of DBS specimens with plasma viral load of 1,000-6,000 copies/ml was 96.2% (76/79). The nucleotide sequence identity was 99.7±0.34% and 99.6±0.25% within and between test runs, respectively. Moreover, there was a near perfect agreement of detecting drug resistance mutations intra- and inter- test runs with kappa value of 0.972 and 0.963, respectively. Between 64 pairs of plasma and DBS specimens, the nucleotide identity was excellent with 99.5±0.34%. As compared to the results of plasma specimens, the sensitivity and specificity for detecting drug resistance mutations in DBS specimens were 99.4 % (95% CI, 97.4-99.8%) and 99.8% (95% CI, 99.7-99.9%), respectively. Totally 15 discordant drug resistance mutations were found. Among them, 53.3 % (8/15) were caused by mixture base. CONCLUSIONS The In-house HIVDR genotyping assay could be used for testing DBS samples with viral load above 1,000 copies/ml in China and had a low intra- and inter- assay variability. DBS is an excellent alternative to plasma for HIV-1 drug resistance genotyping at population levels in China.
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
April 2008,
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
July 2010,
Archives of virology,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
August 2014,
Journal of clinical microbiology,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
April 2024,
Journal of virological methods,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
October 2015,
Journal of virological methods,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
January 2015,
PloS one,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
March 2009,
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
October 1992,
Journal of immunological methods,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
August 2022,
PLoS medicine,
Hai Zhao, and
Lingjie Liao, and
Hui Xing, and
Zhe Wang, and
Bin Su, and
Jia Liu, and
JianJun Wu, and
Yi Feng, and
Cui He, and
Yuhua Ruan, and
Yiming Shao
January 2011,
Antiviral therapy,
